A recent report by Endpoint News takes a look at the Institute for Clinical and Economic Review’s (ICER) recent report on treatments for Duchenne muscular dystrophy.
ICER reviewed Sarepta Therapeutics’ eteplirsen and golodirsen, as well as PTC Therapeutics’ deflazacort. The drug pricing watchdog in its report suggested a massive discount for deflazacort to the tune of 73 percent to make it cost-effective.
“Unfortunately, there is no persuasive evidence that these exon-skipping therapies improve outcomes that matter to patients, including functional status, quality of life, or length of life,” David Rind, ICER’s chief medical officer, said in a statement.
To read the full report on Endpoint News, click here.